Sparteine oxidation is practically abolished in quinidine-treated patients

Br J Clin Pharmacol. 1986 Aug;22(2):194-7. doi: 10.1111/j.1365-2125.1986.tb05250.x.

Abstract

In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day-1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2- and 5-dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • Quinidine / adverse effects*
  • Quinidine / therapeutic use
  • Sparteine / metabolism*

Substances

  • Sparteine
  • Quinidine